Extracorporeal Blood Purification Therapy in Critically Ill Patients: an Interactive, Web-based, Multicenter, Observational Prospective Registry

What this Trial Is About

Extracorporeal Blood Purification (EBP) is increasingly used worldwide in critical care to remove inflammatory mediators in critically ill patients with multiorgan dysfunction, including those with sepsis and acute kidney injury. This research observes the use of EBP therapies, aiming to identify groups of critically ill patients who may benefit most from these treatments. The study also addresses the lack of clear evidence on the impact of bacterial toxin and cytokine removal on mortality rates, particularly in the context of COVID-19-related multiorgan dysfunction. The study collects data through a web-based, interactive registry that allows clinicians from multiple centers to record and analyze EBP treatments, such as Continuous Renal Replacement Therapy and immunomodulation therapies using specialized membranes or cartridges. Treatments are delivered according to local clinical practice without additional interventions, and various clinical and treatment parameters are documented. This registry supports real-time decision-making and research collaboration worldwide. Participants are critically ill patients admitted to intensive care units who receive EBP therapy as part of their routine care. Data collection includes clinical characteristics, treatment details, and outcomes at multiple timepoints up to 10 days after therapy initiation. Researchers monitor clusters of patients to understand treatment effects on short- and long-term outcomes and track usage patterns of EBP worldwide. The study helps clinicians personalize treatment and continuously monitor results during the care of critically ill patients.

Extracorporeal Blood Purification Therapy in Critically Ill Patients (GlobalARRT)